This segment focuses on the development and commercialization of therapies for blood-related cancers, with a primary emphasis on myelofibrosis. Key activities include ongoing clinical trials for pacritinib, an oral kinase inhibitor targeting JAK2, FLT3, IRAK1, and CSF1R. Research efforts are directed towards understanding the molecular mechanisms driving myelofibrosis and identifying novel therapeutic targets. The segment aims to improve patient outcomes by providing effective treatment options for individuals with intermediate or high-risk primary or secondary myelofibrosis. Market positioning involves establishing pacritinib as a leading therapy in the myelofibrosis treatment landscape. Future opportunities include expanding the application of pacritinib to other hematological malignancies and exploring combination therapies to enhance efficacy. Regulatory and clinical aspects involve ongoing monitoring of clinical trial data and adherence to FDA guidelines.